Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

Background We have previously reported significantly longer overall survival (OS) with ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with advanced melanoma, with higher incidences of adverse events (AEs) at 10 mg/kg. This follow-up analysis reports a 5-year update of OS and safety.Method...

Full description

Saved in:

Bibliographic Details
Main Authors:	Dirk Schadendorf, Ralf Gutzmer, Caroline Robert, Celeste Lebbe, Gabriella Liszkay, Inge Marie Svane, Omid Hamid, Paolo Antonio Ascierto, Catriona McNeil, Claus Garbe, Michele Maio, Vanna Chiarion-Sileni, Luc Thomas, Andrzej Mackiewicz, Carmen Loquai, Ana Arance, Piotr Rutkowski, Laurent Mortier, Lars Bastholt, Brigitte Dreno, Marta Nyakas, Jean-Jacques Grob, Michael Smylie, Christoph Hoeller, Virginia Ferraresi, Florent Grange, Joanna Pikiel, Fareeda Hosein, Burcin Simsek, Michele Del Vecchio
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-05-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/8/1/e000391.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

Similar Items